Web2 nov. 2024 · CORE is a global, double-blind, randomized, placebo-controlled, registrational, Phase 3 study in patients with severe hypertriglyceridemia. It is designed to compare … WebAt Ionis, Elaine’s research is focused on understanding the activity of GLP-1 conjugated antisense oligonucleotides in the beta cells of the pancreas. The goal: identifying and advancing new targets for Type 1 and Type 2 diabetes. So, …
Molecular Mechanisms of Antisense Oligonucleotides - Mary …
Web1 jun. 2024 · During the virtual American Association for Cancer Research Annual Meeting 2024, held April 10–15, MacLeod presented preclinical findings on ION537. To develop the drug, his team first did pilot in vivo studies showing that subcutaneously injected ASOs depleting YAP1 in two mouse models of HCC caused tumor regression and increased … WebSr. Research Associate(Core Antisense) at Ionis Pharmaceuticals, Inc. San Diego, California, United States. 101 followers 99 connections. Join to view profile ... how is sqlj different from jdbc
Innovations Podcast Ionis
WebFor more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with our novel antisense technology. Web19 sep. 2024 · We recently showed that translation can be enhanced by antisense oligonucleotides (ASOs) that target upstream open reading frames. Here we report the … Web10 okt. 2024 · ABOUT IONIS PHARMACEUTICALS, INC. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. how is spun honey made